The long-term goal of the Prostate Cancer (PC) Program is to elucidate the pathogenesis of prostatecancer and implement novel approaches to its prevention, early diagnosis, and individualized treatment. Toachieve these ends, the following Specific Goals will be pursued: 1) The molecular oncology of prostatecancer will be elucidated by defining the molecular lesions of proto-oncogenes and tumor suppressorgenes that are responsible for tumor formation; 2) Experimental models of prostate cancer will bedeveloped and characterized to elucidate critical regulatory networks, enhance preclinical studies, anddefine new biological endpoints, including the mechanisms of resistance to certain treatments;3) The experimental therapeutics of prostate cancer will be refined by using molecular determinants tooptimize clinical trials and thereby generate novel decision-making tools for disease management.The PC Program replaces the former Urologic Malignancies Program. It now consists of 19 members (12full members, 4 clinical members, and 3 associate members) from 6 departments within the College ofPhysicians & Surgeons at Columbia University (CD). Compared to the Urologic Malignancies Program, thenew PC Program has fewer members and their interests are more sharply focused on prostate cancer.New leadership has been brought into the Program, with Carlos Cordon-Cardo serving as Program Leaderand Daniel Petrylak as Co-Leader. In the past ten months, major investments by the HICCC led to therecruitment of Dr. Cordon-Cardo, as well a several other outstanding basic and translational investigators,including Edward Gelmann, Cory Abate-Shen, and Michael Shen.The comprehensive nature of the restructured PC Program now ranges from chemoprevention to novelchemotherapy, surgical oncology including minimal invasive procedures, radiation therapy, and quality ofcare programs. The number of trials and the number of patients accrued to such trials have increased.Approximately 78% of clinical trial accruals are of African American or Hispanic ethnicity. Severalinvestigators lead local and multi-center clinical trials. For the last budget year of the grant (July 1, 2006 -June 30, 2007), the PC Program received a total of $7.4M (direct costs) in cancer-relevant grant support,including $1.9M (direct costs) in NCI funding, $1.7M (direct costs) in other cancer-related peer-reviewedfunding, and $3.8M (direct costs) in cancer-related non-peer-reviewed funding. The total number ofpublications since the previous submission was 172, of which 23% were intra-programmatic and 12% interprogrammatic.
| Mumau, Melanie D; Vanderbeck, Ashley N; Lynch, Elizabeth D et al. (2018) Identification of a Multipotent Progenitor Population in the Spleen That Is Regulated by NR4A1. J Immunol 200:1078-1087 |
| Caviglia, Jorge Matias; Yan, Jun; Jang, Myoung-Kuk et al. (2018) MicroRNA-21 and Dicer are dispensable for hepatic stellate cell activation and the development of liver fibrosis. Hepatology 67:2414-2429 |
| Savage, Thomas M; Shonts, Brittany A; Obradovic, Aleksandar et al. (2018) Early expansion of donor-specific Tregs in tolerant kidney transplant recipients. JCI Insight 3: |
| Wu, Wen-Hsuan; Tsai, Yi-Ting; Justus, Sally et al. (2018) CRISPR Repair Reveals Causative Mutation in a Preclinical Model of Retinitis Pigmentosa: A Brief Methodology. Methods Mol Biol 1715:191-205 |
| Jauregui, Ruben; Park, Karen Sophia; Tsang, Stephen H (2018) Two-year progression analysis of RPE65 autosomal dominant retinitis pigmentosa. Ophthalmic Genet 39:544-549 |
| Ishida, Chiaki T; Zhang, Yiru; Bianchetti, Elena et al. (2018) Metabolic Reprogramming by Dual AKT/ERK Inhibition through Imipridones Elicits Unique Vulnerabilities in Glioblastoma. Clin Cancer Res 24:5392-5406 |
| Yen, Bonnie; Fortson, Katherine T; Rothman, Nyanza J et al. (2018) Clonal Bifurcation of Foxp3 Expression Visualized in Thymocytes and T Cells. Immunohorizons 2:119-128 |
| Renz, Bernhard W; Takahashi, Ryota; Tanaka, Takayuki et al. (2018) ?2 Adrenergic-Neurotrophin Feedforward Loop Promotes Pancreatic Cancer. Cancer Cell 33:75-90.e7 |
| Jin, Chun-Hui; Li, Yang; Xia, Jinxing et al. (2018) CXCR4 blockade improves leukemia eradication by allogeneic lymphocyte infusion. Am J Hematol 93:786-793 |
| Bakhoum, Mathieu F; Sengillo, Jesse D; Cui, Xuan et al. (2018) AUTOIMMUNE RETINOPATHY IN A PATIENT WITH A MISSENSE MUTATION IN PITPNM3. Retin Cases Brief Rep 12 Suppl 1:S72-S75 |
Showing the most recent 10 out of 331 publications
